Glioblastoma cancer vaccine ERC1671

Drug Overview

Glioblastoma cancer vaccine ERC1671 is an advanced, personalized immunotherapy designed to fight aggressive brain tumors. In the medical field, it is known as a “cell-based therapeutic vaccine.” Unlike a standard flu shot that prevents illness, this vaccine is a Targeted Therapy used to treat a disease that is already present.

This vaccine is unique because it is “autologous” and “allogeneic.” This means it uses a mixture of the patient’s own tumor cells and tumor cells from other donors. By presenting the immune system with a wide variety of cancer markers, it helps the body recognize and attack brain cancer cells that were previously “hidden” or ignored by the immune system.

• Generic Name: ERC1671 (also known as Gliovac)
• US Brand Names: None (Currently an investigational drug)
• Drug Class: Cancer Vaccine; Immunotherapy
• Route of Administration: Intradermal (Injection into the skin)
• FDA Approval Status: Investigational (Granted FDA Fast Track Designation for Glioblastoma)

What Is It and How Does It Work? (Mechanism of Action)

To understand how ERC1671 works, imagine your immune system is a security team that has forgotten what a “trespasser” looks like. Glioblastoma cells are masters of disguise, often producing signals that “switch off” immune cells.

At the molecular level, ERC1671 works through a multi-layered process:

1. Broad Antigen Exposure: The vaccine contains whole tumor cells that have been killed (inactivated) but still carry all their surface proteins (antigens). By using cells from both the patient and three different donors, the vaccine provides a “Wanted” poster with many different faces of the cancer.
2. Activating the Scouts: When injected into the skin, specialized immune cells called Dendritic Cells (the “scouts”) swallow the vaccine particles.
3. Training the Soldiers: These scouts travel to the lymph nodes and “train” T-cells (the “soldiers”). These T-cells are taught to recognize specific markers on the surface of glioblastoma cells, such as those involved in signaling pathways that drive tumor growth.
4. Breaking the Shield: To ensure the immune system stays active, the vaccine is often given alongside low-dose chemotherapy (Cyclophosphamide) and a high-dose of GM-CSF. These additional treatments help lower the number of “Regulatory T-cells”—cells that the tumor usually uses to protect itself from an immune attack.
5. Targeted Attack: Once trained, the T-cells cross the blood-brain barrier, find the glioblastoma cells, and release chemicals to destroy them while leaving healthy brain tissue alone.

FDA Approved Clinical Indications

As an investigational drug, ERC1671 is currently available only through clinical trials or specialized “Compassionate Use” programs.

Oncological Uses (Investigational)

• Recurrent Glioblastoma Multiforme (GBM): For adult patients whose brain cancer has returned after initial treatment with surgery, radiation, and chemotherapy.
• Grade IV Gliomas: Being researched for other highly aggressive brain tumors.

Non-Oncological Uses

• None. This technology is strictly developed for the treatment of malignant brain tumors.

Dosage and Administration Protocols

ERC1671 is administered in “cycles.” Because it is a vaccine, it is injected into the skin (intradermally) rather than into a vein or the brain directly.

Dose Adjustments:

• Renal/Hepatic Insufficiency: Since this is a cell-based immunotherapy, it is not processed by the liver or kidneys in the same way as traditional drugs. No standard dose adjustments are currently required, though patients are monitored for overall health.

Clinical Efficacy and Research Results

Recent clinical data (2020–2025) has shown that ERC1671 can provide hope for patients who have exhausted other options.

• Overall Survival (OS): In a Phase II trial, patients with recurrent glioblastoma who received ERC1671 combined with Bevacizumab (Avastin) lived significantly longer than those receiving standard care. Numerical data showed a median survival of approximately 12 months compared to 7.5 months in the control group.
• 6-Month Survival: Research indicated that the 6-month survival rate for patients on the vaccine was nearly 100% in specific study groups.
• Disease Control: Over 40% of patients showed a “Partial Response” or “Stable Disease,” meaning the tumor either shrank or stopped growing for a significant period.

Safety Profile and Side Effects

Because ERC1671 uses the patient’s own immune system, it is generally much “gentler” than traditional chemotherapy.

Black Box Warning:

None.

Common Side Effects (>10%)

• Injection Site Reaction: Redness, swelling, or itching where the needle went in.
• Fatigue: Feeling unusually tired or weak.
• Headache: Mild to moderate head pain.
• Flu-like Symptoms: Mild fever or chills (a sign the immune system is “waking up”).

Serious Adverse Events

• Brain Edema: Swelling in the brain (monitored closely via MRI).
• Severe Allergic Reaction: Rare but possible with any biological injection.
• Autoimmune Response: A very rare situation where the immune system attacks healthy tissue.

Management Strategies

• For Site Pain: Cold compresses and standard over-the-counter pain relievers.
• For Brain Swelling: Doctors may use steroids (like Dexamethasone) to reduce inflammation if it occurs.

Connection to Stem Cell and Regenerative Medicine

Research Areas: ERC1671 is at the center of new research involving Regenerative Medicine. Scientists are currently investigating if combining this vaccine with Neural Stem Cell therapies can help repair the damage caused by the tumor after the vaccine has cleared the cancer cells. Furthermore, research is looking at how the “microenvironment” of the brain changes during immunotherapy, potentially allowing for better “stem cell seeding” to regrow healthy brain connections in the future.

Patient Management and Practical Recommendations

Pre-treatment Tests to be Performed

• Tumor Biopsy/Tissue Collection: Fresh tumor tissue from a recent surgery is required to manufacture the personalized part of the vaccine.
• Blood Panel: To ensure the immune system is strong enough to respond to the vaccine.
• MRI Scan: To establish a baseline measurement of the tumor.

Precautions During Treatment

• Steroid Use: High doses of steroids can “dampen” the immune system. Your doctor will try to keep steroid use as low as possible during vaccine cycles.
• Skin Care: Do not apply lotions or creams to the injection site for 24 hours.

“Do’s and Don’ts” List

• Do stay hydrated and rest on the days you receive your injection.
• Do tell your doctor immediately if you experience a seizure or sudden change in vision.
• Don’t be alarmed by a “flu-like” feeling; it often means the vaccine is effectively training your immune system.
• Don’t skip your monthly booster shots, as the immune system needs constant reminders to keep fighting the cancer.

Legal Disclaimer

Standard Medical Information Disclaimer: This guide is for informational purposes only and does not constitute medical advice. Glioblastoma cancer vaccine ERC1671 is an investigational drug and is currently only available through clinical trials or approved access programs. Always consult with a licensed oncologist or neuro-oncologist to discuss treatment options, risks, and benefits specific to your medical history. This information reflects clinical data available as of 2026.